Medicare outsources lab pricing to a single nonprofit data broker

What it does

This bill rewrites how Medicare pays for clinical diagnostic laboratory tests by requiring CMS to contract with an independent nonprofit data entity to collect private insurance claims data (at least 50 billion claims from 50+ insurers) and use that data to set Medicare payment rates instead of relying solely on lab-reported data. The bill phases in this new data-collection system starting in 2027–2028, with fallback protections (CPI adjustments) if no data contract exists or data is unavailable. The stated goal is to improve accuracy and stability of lab test payment rates; the practical effect is to shift Medicare pricing away from lab self-reporting toward market-based private payor rates, potentially lowering payments for labs and raising transparency around how rates are calculated.

Why we flagged it

The bill's core mechanism is a structural shift in how CMS determines lab test payment rates—from lab-reported data to private claims data collected by a contracted nonprofit entity. This is a regulatory redesign, not a simple rate adjustment, and it centralizes pricing authority in a single data intermediary.

What the text implies

• A single nonprofit data entity becomes the de facto arbiter of Medicare lab pricing for 'widely available' tests; if that entity fails, is compromised, or loses its data contract, Medicare defaults to CPI-only adjustments, potentially freezing rates below market for years.
• Labs lose direct control over the data used to set their payment rates; private payor claims data may not reflect their actual costs, especially for rural, safety-net, or specialized labs serving lower-volume populations.
• The bill excludes Medicaid managed care data from the private payor database, potentially understating true market rates and creating a two-tier payment system where Medicare rates diverge from Medicaid.
• Beneficiaries in areas where labs exit or reduce service due to payment pressure may face longer wait times or travel burden for lab tests, particularly if the affected labs serve rural or underserved communities.
• The 'final payment rate' definition excludes denied, appealed, and erroneous payments, which may systematically understate actual payor costs and bias Medicare rates downward.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Medicare beneficiaries may benefit from more accurate, market-based lab test pricing and reduced overpayment to labs, but the bill's reliance on a single nonprofit data intermediary and its fallback CPI-only adjustments create implementation risk and potential payment volatility. Labs face payment pressure, which could reduce service availability or quality in underserved areas; beneficiaries in those areas bear the cost.

Who stands to gain

• Medicare program (reduced lab test payments)
• Private insurers (their claims data becomes the pricing benchmark, potentially validating their nego
• The contracted nonprofit data entity (receives CMS contract and operational funding)

Named in the bill

Centers for Medicare & Medicaid Services (CMS), Clinical diagnostic laboratories, Private payors and claims administrators, Qualifying independent claims data entity (nonprofit, to be identified), Medicare beneficiaries, Advanced diagnostic laboratory tests (ADLTs), Medicaid managed care organizations

Where it stands

123 cosponsors: 63 Republicans, 60 Democrats.

• Sep 10, 2025 — Introduced · Congress.gov: “Introduced in House”
• Sep 10, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

38 lobbying clients named this bill on 61 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $20,477,337 in lobbying spend. A filing names 5 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 99% of bills with at least one filing.

Richard Hudson, the sponsor, reported $1,733,644 in PAC receipts in the 2026 cycle. $2,000 of that came from 1 PAC tied to these lobbying clients.

• American Hospital Association — $4,470,000 on 1 filing
• American Cancer Society Cancer Action Network Inc — $3,620,000 on 2 filings
• Advanced Medical Technology Assn — $1,913,000 on 2 filings
• American Clinical Laboratory Assn — $1,820,000 on 2 filings
• American Academy of Family Physicians — $1,715,904 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.